Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World

Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

Published:2023-08-23 Issue:5 Volume:23 Page:583-593
ISSN:1175-3277
Container-title:American Journal of Cardiovascular Drugs
language:en
Short-container-title:Am J Cardiovasc Drugs

Author:

Seijas-Amigo Jose^ORCID,Mauriz-Montero Mª José,Suarez-Artime Pedro,Gayoso-Rey Mónica,Estany-Gestal Ana,Casas-Martínez Antonia,González-Freire Lara,Rodriguez-Vazquez Ana,Pérez-Rodriguez Natalia,Villaverde-Piñeiro Laura,Castro-Rubinos Concepción,Espino-Faisán Esther,Rodríguez-Mañero Moisés,Cordero Alberto,González-Juanatey José R.,Paz-Couce Adrián,Rodriguez-Penas Diego,Cardeso-Paredes Begoña,Seoane-Blanco Ana,Moure-Gonzalez María,Soler-Martín Rita,Margusino-Framiñan Luis,Suarez-Rodriguez Ana,Rodriguez-Cobos Marisol,Rojo-Valdés Juan,Zarra-Ferro Irene,Lorenzo-Lorenzo Karina,Casanova-Martinez Cristina,Crespo-Diz Carlos,Dominguez-Guerra María,González-Pereira María Elena,Anido-García María,Tajes-Gonzalez Iveth Michelle,Mozo-Peñalver Héctor,Silva-Lopez Alicia,Rodriguez-Sanchez Jose Luis,García-Verde María Jesús,

Funder

Universidade de Santiago de Compostela

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40256-023-00604-6.pdf

Reference31 articles.

1. Silverman MG, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. J Am Med Assoc. 2016;316(12):1289–97.

2. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:e285–350.

3. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111–88. https://doi.org/10.1093/eurheartj/ehz455.

4. Jellinger PS, Handelsman Y, Rosenblit P, Bloomgarden ZT. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(April):1–24.

5. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/ AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73(24):e285–350. https://doi.org/10.1016/j.jacc.2018.11.003.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCSK9 inhibitor effectively alleviated cognitive dysfunction in a type 2 diabetes mellitus rat model;PeerJ;2024-08-14

2. Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression;Current Medical Research and Opinion;2024-06-11

3. Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran;Journal of the American Heart Association;2024-03-19